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Abstract
17b-Hydroxysteroid dehydrogenase type 1 (17b-HSD1) catalyzes the reduction of estrone to estradiol, which is the most
potent estrogen in humans. Inhibition of 17b-HSD1 and thereby reducing the intracellular estradiol concentration is thus a
promising approach for the treatment of estrogen dependent diseases. In the past, several steroidal and non-steroidal
inhibitors of 17b-HSD1 have been described but so far there is no cocrystal structure of the latter in complex with 17b-
HSD1. However, a distinct knowledge of active site topologies and protein-ligand interactions is a prerequisite for structure-
based drug design and optimization. An elegant strategy to enhance this knowledge is to compare inhibition values
obtained for one compound toward ortholog proteins from various species, which are highly conserved in sequence and
differ only in few residues. In this study the inhibitory potencies of selected members of different non-steroidal inhibitor
classes toward marmoset 17b-HSD1 were determined and the data were compared with the values obtained for the human
enzyme. A species specific inhibition profile was observed in the class of the (hydroxyphenyl)naphthols. Using a
combination of computational methods, including homology modelling, molecular docking, MD simulation, and binding
energy calculation, a reasonable model of the three-dimensional structure of marmoset 17b-HSD1 was developed and
inhibition data were rationalized on the structural basis. In marmoset 17b-HSD1, residues 190 to 196 form a small a-helix,
which induces conformational changes compared to the human enzyme. The docking poses suggest these conformational
changes as determinants for species specificity and energy decomposition analysis highlighted the outstanding role of
Asn152 as interaction partner for inhibitor binding. In summary, this strategy of comparing the biological activities of
inhibitors toward highly conserved ortholog proteins might be an alternative to laborious x-ray or site-directed mutagenesis
experiments in certain cases. Additionally, it facilitates inhibitor design and optimization by offering new information on
protein-ligand interactions.
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Introduction
Human 17b-hydroxysteroid dehydrogenase type 1 (17b-HSD1)
catalyzes the NAD(P)H dependent reduction of the weak estrogen
estrone (E1) to the biologically most active estrogen estradiol (E2;
Fig. 1) [1]. This reaction, which represents the last step in E2
biosynthesis, takes place in target cells where the estrogens exert
their effects via the estrogen receptors a and b. Besides their
physiological effects, estrogens are involved in the development
and the progression of estrogen dependent diseases (EDDs) like
breast cancer, endometriosis and endometrial hyperplasia [2–4].
In the past few years, aromatase inhibitors have been intensively
investigated for the treatment of EDDs [5–7] but they lead to
unwanted side effects due to their strong reduction of estrogen
levels in the whole body. Therefore reducing local E2 levels by
inhibition of 17b-HSD1 is a promising therapeutic approach for
the treatment of EDDs. An analogous intracrine concept has
already been proved successful for the treatment of androgen
dependent diseases such as benign prostatic hyperplasia and
alopecia by using 5a-reductase inhibitors [8–11]. 17b-HSD2
catalyzes the reverse reaction (oxidation of E2 to E1; Fig. 1) and
inhibition of this enzyme must be avoided for the therapeutic
concept to work. However, specific inhibition of 17b-HSD2 in
bone cells may provide a novel approach to prevent osteoporosis
[12].
17b-HSD1 is a cytosolic enzyme that belongs to the super-
familiy of short-chain dehydrogenases/reductases (SDRs) [13]. It
consists of 327 amino acid residues (34.9 kDa) and the active form
exists as homodimer [14]. 17b-HSD1 comprises a Rossmann fold,
associated with cofactor binding, and a steroid-binding cleft [15].
The latter is described as a hydrophobic tunnel with polar residues
at each end: His221/Glu282 on the C-terminal side, and Ser142/
Tyr155, belonging to the catalytic tetrad, which is present in the
majority of characterized SDRs [16], on the other side [17]. To
date 22 crystal structures of 17b-HSD1 are available as apoform,
binary or ternary complexes [18–20]. All crystal structures show
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22990an overall identical tertiary structure, while major differences have
been identified only for the highly flexible bFaG’-loop. It is not
resolved in ten crystal structures, while the remaining twelve
showed high b-factor values for this area, which is an additional
hint for the flexibility of the bFaG’-loop. In some crystal structures
a short a-helix was observed in the loop region but its occurrence
seems not to be dependent on the presence of steroidal ligands,
cofactor or inhibitor. However, the position and length of the a-
helix changes: in the apoform (PDB entry 1bhs) the helix is limited
to the beginning of the loop while in presence of steroidal ligands
and/or cofactor it is shifted to the end (PDB entries 1dht, 1equ,
and 1iol). Further, dependent on the presence of cofactor and
ligands, the bFaG’-loop can occupy three possible orientations: an
opened, semi-opened, and closed enzyme conformation [21].
Several steroidal and non-steroidal inhibitors of 17b-HSD1
have been described [18,22–37], but only for the former cocrystal
structures exist. While several computational studies have been
performed in order to elucidate the interactions of non-steroidal
inhibitors with 17b-HSD1 [26,27,33,37,38], structural data
confirming the results are still missing.
However, a distinct knowledge of active site topologies and
protein-ligand interactions is a prerequisite for structure-based
drug design and optimization. To further increase this knowledge,
inhibition values obtained for one compound toward proteins,
differing only in few residues might be advantageous. For this
purpose, wild type proteins and their mutants carrying a set of
point mutations can be used. As alternative, proteins from various
species, which are highly conserved in sequence and differ only in
few residues, might be considered.
This latter approach was applied in the present study employing
human and marmoset monkey (callithrix jacchus)1 7 b-HSD1.
Selected human 17b-HSD1 inhibitors, representative of our
structurally diverse inhibitor classes, were tested toward the
marmoset 17b-HSD1. The resulting inhibitory potencies were
compared with those obtained for the human enzyme and
remarkable differences were only observed in the class of the
(hydroxyphenyl)naphthols. In order to rationalize the species-
specific inhibition profiles at the structural basis, a homology
model of the marmoset enzyme was built using a human 17b-
HSD1 x-ray structure as template. Further, the docking poses of
selected compounds into both the human crystal structure and the
modelled marmoset 17b-HSD1 were considered. Notably, the
marmoset homology model and the docking poses of the inhibitors
presented herein were validated by their ability to explain
inhibition data. Subsequently, the complexes of two representative
inhibitors, docked into the marmoset model and the human crystal
structure, respectively, were subjected to MD simulations to
investigate their conformational equilibrium. In addition, binding
energy calculations as well as energy decomposition analysis were
performed, with the aim to investigate the influence of the
marmoset amino acid variations on the inhibitory potencies. The
current work provides new insights into the marmoset 17b-HSD1
active site topology, reveals probable inhibitor binding modes in
human and marmoset 17b-HSD1, and identifies amino acids
responsible for species specificity in 17b-HSD1 inhibition.
Results
Comparison of 17b-HSD type 1 and type 2 sequences
To identify regions that are conserved through several species,
the sequences of rodent, cynomolgus, marmoset and human 17b-
HSDs 1 were aligned (Fig. 2A). The N-terminal region (residues 1–
190), which constitutes the common Rossmann fold as well as the
catalytic tetrad, is highly conserved for the analyzed species.
Remarkable differences were observed in the F/G segment
(residues 191–230), which is lining the steroid-binding site, and
the C-terminal region (residues 231–285). Sequence alignment of
human and marmoset 17b-HSD1 revealed that they share 80%
sequence identity and 85% similarity (Fig. 2A). Focusing on the
steroid-binding site (residues 94 to 196 and 214 to 284), the
identity increases to 87%, with five major amino acid variations
observed in the marmoset enzyme: A191P, E194Q, S222N, V225I
and E282N. In contrast, comparing cynomolgus and human 17b-
HSD1, which show even 91% identity, only one of the
aforementioned amino acid variations can be found (E282H;
Fig. 2A). With the exception of marmoset 17b-HSD1, Ala191 and
Glu194 are conserved through the analyzed species (Fig. 2A)
indicating the significance of the observed variations between
human and marmoset. 17b-HSDs 1 of mouse and rat are 83%
similar to the human enzyme in the first 287 amino acids. In both
analyzed rodent enzymes His221, which is involved in steroid
binding [17], is mutated into a glycine (H221G). Moreover, several
other amino acids of the substrate-binding site are replaced by
more bulky residues (L96F, N152H, M193Y/H, S222Y). Inter-
estingly, rat and mouse 17b-HSDs 1 are significantly less sensitive
to inhibition by steroidal inhibitors compared to the human
ortholog [39] and different classes of non-steroidal potent human
17b-HSD1 inhibitors turned out to be only weak inhibitors of E2
formation in rat liver preparations [40]. This might be partially
explained by the absence of His221 as interaction partner as well
as by the reduced volume of the active site (M193Y/H, S222Y).
Sequence identities between human 17b-HSD2 and 17b-HSD2
of the selected species range from 61% (mouse) to 93%
(cynomolgus) while the F/G segment and the C-terminal region
show the most pronounced variability (Fig. 2B). The comparison
of 17b-HSD1 with the correspondent type 2 enzymes of the
analyzed species revealed, that the type 2 enzymes have about 80
additional N-terminal residues relative to the type 1 enzymes.
Sequence comparison showed that they share a very low overall
sequence identity (#25%) with major differences in the F/G
segment and the C-terminal domain, which constitute the active
site. However, some amino acid motifs, characteristic for SDR
enzymes [18], are highly conserved: the T-G-xxx-G-x-G motif, the
Y-xxx-K sequence and the N-A-G motif (Fig. 2B). For marmoset
17b-HSD2 only a fragment of the primary sequence is available,
which is 143 amino acids in length and constitutes the Rossman
fold whereas the F/G segment and the C-terminal region are
missing (Fig. 2B). This segment is 29% identical to marmoset
17b-HSD1.
As human and marmoset 17b-HSD1 differ in few residues of
the active site, comparison of the inhibitory potencies of selected
inhibitors, observed toward both enzymes, is suitable to further
increase the knowledge of active site topologies and protein-ligand
interactions. In particular, the amino acid variations in the flexible
bFaG’-loop, which is suggested to play a crucial role in ligand
binding, will be used to elucidate the function of the loop in more
detail.
Figure 1. Interconversion of estrone (E1) and estradiol (E2).
doi:10.1371/journal.pone.0022990.g001
Structural Basis for 17b-HSD1 Species Specificity
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e22990Inhibition of marmoset 17b-HSD1 and 17b-HSD2
Marmoset placental tissue was used as enzyme source and the
proteins were partially purified following a described procedure
[41]. Tritiated E1 was incubated with 17b-HSD1, cofactor and
inhibitor. The separation of substrate and product was performed
by HPLC. In an assay similar to the 17b-HSD1 test, marmoset
placental microsomes containing 17b-HSD2 were incubated with
tritiated E2 in the presence of NAD
+ and inhibitor. Labelled
product was quantified after HPLC separation.
The inhibition values of compounds 1–20 (Fig. 3) are shown in
Table 1. The bis(hydroxyphenyl) substituted arenes 1–11 showed
comparable or even higher inhibitory potencies toward marmoset
17b-HSD1 compared to the human enzyme. For example,
compound 8, which is a potent inhibitor of human 17b-HSD1
(IC50=151 nM), showed a stronger inhibitory potency toward
marmoset 17b-HSD1 (IC50=4 nM). Comparable inhibition data
for human and marmoset 17b-HSD1 were also measured for the
bicyclic substituted hydroxyphenylmethanones 12 and 13. This
indicates that the binding of the two aforementioned inhibitor
classes is reinforced or at least not affected by the amino
acid variations in marmoset 17b-HSD1. In the class of the
(hydroxyphenyl)naphthols, the human 17b-HSD1 inhibitor 14
(IC50=116 nM) showed also a good inhibitory potency toward
marmoset 17b-HSD1 (IC50.50 nM). The introduction of space
filling substituents in position 1 of the naphthol core of 14 is
beneficial for the inhibition of the human enzyme (16,
IC50=26 nM), but for marmoset 17b-HSD1 no increase in
inhibitory potency was observed (16,I C 50.50 nM) compared to
the unsubstituted 14. Interestingly, further enlargement of the
substituents in 1-position of 14 led to highly active human 17b-
HSD1 inhibitors (19,I C 50=15 nM) while a reduced potency
toward marmoset 17b-HSD1 (19,I C 50.50 nM) was found.
The inhibitory potencies of compounds 1–20 toward marmoset
17b-HSD2 were also determined to prove whether marmoset
monkey is a suitable species for in vivo evaluation of 17b-HSD1
inhibitors (Table 1). Remarkably, lower selectivity of compounds
toward non-target marmoset 17b-HSD2 was observed, when
comparing to human 17b-HSD2.
Homology modelling and MD simulations of marmoset
17b-HSD1
In order to obtain a more precise picture of the three-
dimensional structure of the marmoset 17b-HSD1, a homology
model was generated. A set of 100 models was built with
MODELLER 9v7 [42] using the ternary complex E1-NADPH-
human 17b-HSD1 as template. This complex was obtained by
docking E1 into human 17b-HSD1 employing the Protein Data
Bank (PDB) entry 1fdt with conformation B for residues 187–200
(in the following determined as 1fdtB). This 3D structure was
chosen as it represents a ternary complex with NADP
+ and E2 in
the closed enzyme conformation, as the bFaG’-loop is resolved,
and as this protein structure was already successfully used in
previous docking studies with the investigated compound classes
[30,36]. The best model was chosen according to internal DOPE-
score [43] and PROCHECK [44] tests. Notably, it presents a
short a-helix (residues 190–196) in the region between the bF-
Figure 2. Multiple sequence alignment of 17b-HSD type 1 and type 2 from selected species. Species and subtype are indicated on the left,
followed by residue numbering. Residues are colored by percentage identity and red arrows indicate major amino acid variations in marmoset
compared to the other species. A) Multiple sequence alignment of 17b-HSD1 from selected species. B) Multiple sequence alignment of human 17b-
HSD1 with 17b-HSD2 from selected species.
doi:10.1371/journal.pone.0022990.g002
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with Pro191 in the first turn of the helix (N1 position; Fig. 4), thus
differing from the secondary structure of the template.
The selected model was further refined both as holoenzyme
with NADPH and as ternary complex with NADPH and E1 by
MD simulations. The trajectories of the two MD simulations were
stable with a a-carbon root-mean-square deviation (RMSD) to the
starting structure below 3.0 A ˚ (Fig. 5). No major structural
differences were observed when comparing the simulated
holoenzyme and the ternary complex. Therefore, the following
results, based on analysis of the ternary complex, also apply to the
holoform.
After an initial inward rotation in the MD simulation, the short
a-helix (residues 190–196) remained stable for the last 5 ns of the
Figure 3. Chemical structures of selected human 17b-HSD1 inhibitors. Representative structures of our three inhibitor classes: the
bis(hydroxyphenyl) substituted arenes (1–11), the bicyclic substituted hydroxyphenylmethanones (12, 13) and the (hydroxyphenyl)naphthols
(14–20).
doi:10.1371/journal.pone.0022990.g003
Table 1. Inhibition of human and marmoset 17b-HSD1 and 17b-HSD2 by compounds 1–20.
Human IC50 [nM] Marmoset IC50 [nM]
c
compd X R1 R2 R3 17ß-HSD1
a 17ß-HSD2
b 17ß-HSD1
d 17ß-HSD2
e
1 CH F H 8 940 ,5
f .50
2 N H H 50 4004 102 .50
3 CH H H 69 1953 31 .50
4 CH CH3 H 46 1971 ,50 .50
5 NC H 3 H 143 2023 ,50 .50
6 CH H F 42 463 ,5
f 85
7 CH F F 17 218 ,5
f 43
8 4-OH OH H 151 1690 4
f .50
9 3-OH H OH 77 1271 2
f .50
10 3-OH CH3 OH 64 869 3
f .50
11 3-OH F OH 64 510 ,50 72
12 H OH 33 478 ,50 43
13 OC2H5 78 502 ,50 59
14 116 5641 .50 .50
15 C OH 36 959 32 .50
16 N 26 1157 .50 .50
17 C H 20 540 52 .50
18 CN H 2 53 1757 n.i. .50
19 C NHSO2CH3 15 403 .50 .50
20 C NHCOCH3 83 1239 .50 n.i.
aHuman placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 mM;
bHuman placental, microsomal fraction, substrate E2, 500 nM, cofactor NAD
+, 1500 mM;
cLogit transformed values calculated from % inhibition at 50 nM inhibitor concentration, for inhibition values ,30% or .70%, a trend is given;
dMarmoset monkey placental, cytosolic fraction, substrate E1, 500 nM, cofactor NADH, 500 mM;
eMarmoset monkey placental, microsomal fraction, substrate E2, 500 nM, cofactor NAD
+, 1500 mM;
fInhibitor concentration: 5 nM; n.i.: no inhibition; Human IC50 values were retrieved from literature (corresponding references are indicated with the structural formulas
in Fig. 3).
doi:10.1371/journal.pone.0022990.t001
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conformation of 1.03 A ˚. Remarkably, a similar behaviour cannot
be expected for the region between the bF-sheet and the aG’-helix
in the human enzyme. The differences in the crystal structures
suggest a high flexibility for the bFaG’-loop: it is not resolved in
ten crystal structures and the remaining twelve show high b-factor
values for this area. Some crystal structures present a short a-helix
in the loop region whose position and length varies dependent on
the presence of steroidal ligands, cofactor or inhibitor. In the
apoform (PDB entry 1bhs) the helix is limited to the beginning of
the loop, whereas in presence of steroidal ligands and/or cofactor
it is shifted to the end (PDB entries 1dht, 1equ, and 1iol). Further,
in the human enzyme, the bFaG’-loop axis occupies different
orientations dependent on the presence of cofactor and ligands. In
the marmoset however, both the holoform and the ternary
complex show a helix starting already at the beginning of the
bFaG’-loop with its axis in only one conformation.
The presence of the newly formed a-helix (residues 190–196)
induced a different orientation of the side chain of Met193.
Compared to the template structure, Met193 protrudes deeper into
the substrate-binding site and stabilizes E1 by hydrophobic
interactions (Fig. 4). Furthermore, during MD simulation a kink
in the loop between the bD-sheet and the aE-helix was observed.
Thereby the side chain of Leu96 was brought closer to E1 allowing
Van der Waals contacts (Fig. 4). Summarizing, in the final part of
the MD simulation E1 was stabilized by both lipophilic interactions
and hydrogen bonds: Leu96, Leu149, Met193, and Phe259
constrained the steroidal scaffold while Ser142/Tyr155 and
His221/Asn282 interacted with the carbonyl oxygen in 17-position
and the 3 OH-group, respectively. The latter residue took over the
H-bond acceptor abilities of Glu282, which is involved in forming
an H-bond with the 3 OH-group of E1 in the human enzyme.
Employing CASTp [45], the active site volumes of human and
marmoset 17b-HSD1 were calculated. The above-described
conformational changes of Leu96 and Met193 as well as the
S222N and V225I mutations resulted in a reduced volume of the
marmoset 17b-HSD1 active site (478 A ˚ 3) compared to that of the
human ortholog (627 A ˚ 3).
The stereochemical quality of the holoenzyme and the ternary
complex models obtained from MD simulations was checked with
PROCHECK [44]. The majority of the residues of the
investigated structures were found to occupy the most favoured
regions of the Ramachandran plots, while the other residues
occupied the additional allowed regions. In detail, in the ternary
complex 78.1% of the residues were placed in the most favoured
region, 20.2% in the additional allowed region, 1.2% in the
generously allowed region, and only 0.4% in the disallowed region
(for the holoform: 81.8%, 17.4%, 0.8% and 0%).
Molecular docking
As the potent inhibitors of human 17b-HSD1 12 and 19 are
structurally diverse and exhibit different potencies toward
Figure 4. Three-dimensional structure superimposition of marmoset and human 17b-HSD1. Low energy structure of marmoset 17b-
HSD1 (green) in complex with E1 and NADPH (orange) from MD simulation superimposed onto the x-ray structure of human 17b-HSD1 (grey, PDB
code: 1fdtB). When two residues are indicated, the first corresponds to marmoset 17b-HSD1 and the second to human 17b-HSD1.
doi:10.1371/journal.pone.0022990.g004
Figure 5. RMSD analysis of the MD simulations of the
marmoset 17b-HSD1 model. Time-dependent Ca-RMSD for all
residues of the secondary (orange) and ternary (green) complex.
doi:10.1371/journal.pone.0022990.g005
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rationalize the observed species-specific inhibition profiles. Em-
ploying AutoDock 4 [46], both compounds were docked into the
active sites of marmoset and human 17b-HSD1 using the
equilibrated, ternary complex after 5537 ps and the x-ray
structure 1fdtB (see experimental part), respectively. The inhibitor
poses used for further investigation were selected considering
binding energy and statistical representativity (cluster population;
Table S1) and are shown in Figure 6.
In the human enzyme both inhibitors are placed in the
substrate-binding site and they occupy an apolar subpocket
consisting of the following amino acids: Gly94, Leu95, Leu96,
Asn152, Tyr155, and Phe192 (Fig. 6A). While the carbonyl group
of compound 12 mimics the D-ring keto function of E1, forming
H-bonds with Ser142 and Tyr155, its para-OH group resembles
the 3-OH of E1, which interacts with His221 via an H-bond. The
meta-hydroxyphenyl moiety is projecting into the subpocket, where
it forms an additional H-bond with Asn152 and is stabilized by p-
p-interactions with Tyr155 and Phe192.
The (hydroxyphenyl)naphthol-core of compound 19 occupies
the substrate-binding site and is stabilized by three H-bonds: the 2-
OH group interacts with Ser142 as well as with Tyr155 and the
OH group in meta position of the phenyl ring in 6-position interacts
with His221. In this case, the sulfonamide substituted phenyl ring
in 1-position of the naphthol core protrudes into the subpocket,
where it is stabilized by H-bonds with Asn152 and with the -NH-
of the backbone of Leu95 (Fig. 6A).
Also in the marmoset enzyme both compounds occupy the
substrate-binding site, but only 12 protrudes into the apolar
subpocket (Fig. 6B). Due to the altered side chain conformation of
Leu96 in the marmoset enzyme, compound 12 is slightly displaced
toward the C-terminus (Fig. 6C). Regarding the interaction
Figure 6. Hypothetical binding modes of compounds 12 and 19. A) Superimposition of lowest energy structures of 12 (orange) and 19
(cyan) obtained by docking into the x-ray structure of human 17b-HSD1 (magenta, PDB code: 1fdtB). B) Superimposition of lowest energy structures
of 12 (light green) and 19 (yellow) obtained by docking into the marmoset 17b-HSD1 homology model (green). C) Superimposition of lowest energy
structures of 12 (light green) docked into the marmoset 17b-HSD1 model (green) and of 12 (orange) docked into the x-ray structure of human 17b-
HSD1 (magenta, PDB code: 1fdtB). D) Superimposition of lowest energy structures of 19 (yellow) docked into the marmoset 17b-HSD1 model (green)
and of 19 (cyan) docked into the x-ray structure of human 17b-HSD1 (magenta, PDB code: 1fdtB).
doi:10.1371/journal.pone.0022990.g006
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forms only an H-bond with Ser142 but for the para-OH group a
second H-bond with Asn282 was observed (Fig. 6C).
Interestingly, compound 19 resulted in a completely different
binding mode when docked into the homology model of marmoset
17b-HSD1 with respect to its position in the human crystal
structure 1fdtB (Fig. 6D). The OH-group in meta position of the
phenyl ring makes an H-bond with the backbone carbonyl oxygen
of Cys185 and the 2-OH function forms H-bonds with His221 and
Asn282 in a bifurcated fashion. The sulfonamide substituted
phenyl ring is located in the C-terminal gate and might be
stabilized by p-p-interactions with Phe259 and an H-bond with
the backbone -NH- of Leu262.
Validation of the docking complexes by means of MD
simulations and free energy calculations (MM/PBSA)
With the aim to validate the docking results and to unravel
possible induced-fit mechanisms, different MD simulations were
run in explicit aqueous solution. Distance restraints were applied
to inhibitors only in the first ns of the MD simulations with the aim
of maintaining their proper orientation. For the rest of the MD
simulation no restraints were used and the whole complexes were
left free to move. This was done in order to avoid trapping the
inhibitor in an unstable conformation, which could bias the results.
The RMSD values of the heavy atoms of the inhibitors and of the
Caatoms of the enzymes were analyzed as a function of time to
assess the degree of conformational drift, as shown in Figure 7.
In the simulation of 12 bound to human 17b-HSD1 the
CaRMSD of the protein as well as the RMSD of the heavy atoms
of 12 showed a stable plateau (,2.2 A ˚) from 1.0 to 2.5 ns (Fig. 7A).
After 2.5 ns the CaRMSD of the protein increased and a minor
fluctuation of the heavy atom RMSD of 12 was observed. The
latter finding could be related to a slight shift of the inhibitor
toward the C-terminal end of the enzyme. Notably, the hydrogen
bonds between 12 and 17b-HSD1, which were observed in the
initial structure, were conserved during the 4 ns simulation
suggesting that both protein and 12 fluctuations do not impact
the inhibitor binding.
Both human 17b-HSD1 and compound 19 were stable in the
simulation of their complex (Fig. 7B). During the simulation (after
1.5 ns) the hydrogen bond of the meta-OH group with His221 is
replaced by an H-bond with Glu282. However, after 2.1 ns, this
hydrogen bond is interrupted for 0.2 ns allowing the hydro-
xyphenyl ring to rotate freely around the axis of the bond to the
naphthol core thereby inducing a minor fluctuation of the heavy
atom RMSD of 19. After this short interruption the H-bond
interaction with Glu282 is re-established. On the other side, the
hydrogen bonds between the 2-OH group and Ser142/Tyr155 as
well as between the sulfonamide moiety and Asn152/Leu95
endured constant.
During the MD simulation of 12 in complex with marmoset
17b-HSD1, the meta-hydroxyphenyl moiety of 12 moved further
out of the subpocket. This was reflected by the minor fluctuation of
the RMSD of the heavy atoms of 12 after 1.4 ns (Fig. 7C). While
this motion caused the break of the H-bond with Asn152, it also
placed the meta-OH group in an appropriate distance to Asn222,
thus allowing a new H-bond formation.
The analysis of the MD simulation of the marmoset 17b-HSD1-
19 complex revealed an overall stable CaRMSD of the protein.
However, after 1.8 ns, a ,0.5 A ˚ fluctuation of the heavy atom
RMSD of 19 was observed (Fig. 7D) corresponding to the rotation
Figure 7. Time dependent RMSD analysis of Ca of 17b-HSD1 and of the heavy atoms in the ligands. A)C a-RMSD of human 17b-HSD1 is
colored in magenta and the heavy atoms RMSD of compound 12 in light green. B)C a-RMSD of human 17b-HSD1 is colored in magenta and the
heavy atoms RMSD of compound 19 in yellow. C)C a-RMSD of marmoset 17b-HSD1 is colored in green and the heavy atoms RMSD of compound 12
in light green. D)C a-RMSD of marmoset 17b-HSD1 is colored green and the heavy atoms RMSD of compound 19 in yellow.
doi:10.1371/journal.pone.0022990.g007
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the naphthol core. Thereby the H-bond with the backbone amino
group of Leu262 was lost.
Furthermore, for each of the four MD trajectories absolute free
energy (DG) and relative binding affinity (DGbind) were calculated
applying MM/PBSA methods and NMODE analysis (Table 2). This
was done for the following stable sectors: 1000 to 2500 ps for 12 in
complex with human 17b-HSD1 (Fig. 7A), 2300 to 4160 ps for 19
in complex with human 17b-HSD1 (Fig. 7B), 1500 to 4160 ps for 12
in complex with marmoset 17b-HSD1 (Fig. 7C) and 1800 to 4160 ps
for 19 in complex with marmoset 17b-HSD1 (Fig. 7D). All
four complexes showed favourable DG values, ranging from
27.3 kcal mol
21 to 23.2 kcal mol
21. The free energies observed
for compound 12 in complex with human (DG=24.7 kcal mol
21)
and marmoset 17b-HSD1 (DG=25.8 kcal mol
21) are in the same
range. This is in accordance with the inhibitory activities of 12,w h i c h
are comparable for both species (see Table 1). Regarding compound
19, the complex with human 17b-HSD1 shows a more favourable
free energy (DG=27.3 kcal mol
21)t h a nt h eo n ew i t hm a r m o s e t
17b-HSD1 (DG=23.2 kcal mol
21). This is mainly due to poor
entropiccontributionsin thelattercase.Remarkably,thisfinding isin
concert with the experimentally determined inhibition data:
compound 19 is a highly potent human 17b-HSD1 inhibitor
(IC50=15 nM) with reduced activity toward the marmoset enzyme
(IC50.50 nM).
Analysis of the binding interactions using MM/GBSA methods
Focusing on the specific interactions, which mediate the binding
of 12 and 19 to human and marmoset 17b-HSD1, we have
analyzed the interaction energies of both inhibitors with the
residues of the binding sites, employing a pairwise per-residue
energy decomposition analysis.
Inspection of the interaction energies with human 17b-HSD1
(Table 3) showed that the hydrogen bonds of 12 (24.1 kcal mol
21)
and 19 (25.7 kcal mol
21) with Asn152 contributed most to the
interaction energies. Besides Asn152, further residues of the
subpocket (Gly94, Leu95, Leu96) interact with both inhibitors
revealing energies from 20.3 kcal mol
21 to 21.8 kcal mol
21. The
energies of the hydrogen bonds between 12 and the catalytic
residues Ser142 as well as Tyr155 are 21.3 kcal mol
21 and
21.5 kcal mol
21, respectively. In case of compound 19 the
interaction energies are 21.3 kcal mol
21 for the H-bond with
Ser142 and 21.3 kcal mol
21 for the H-bond with Tyr155. Further
bindingsite residues,which significantly contributeto the binding of
compounds 12 and 19 (Leu149, Pro187, Phe192, Met193, Val225,
and Phe259) show interaction energies from 20.9 kcal mol
21 to
22.2 kcal mol
21. Regarding the polar amino acids at the C-
terminal end of the binding site, His221 takes primarily part in the
binding of 12 (21.8 kcal mol
21 for 12 vs. 20.2 kcal mol
21 for 19)
while Glu282 is mainly involved in binding compound 19
(20.1 kcal mol
21 for 12 vs. 24.3 kcal mol
21 for 19).
The interaction energies of 12 and 19 with marmoset 17b-
HSD1 are listed in Table 4. Remarkably, for inhibitor 12, the
energy contribution of the H-bond with the marmoset Asn152
(21.6 kcal mol
21) is 2.6 fold reduced compared to the human
enzyme, while for compound 19 it is almost lost (20.2 kcal -
mol
21). Both for 12 and 19 reduced energies were also observed
for interactions with Gly94, Leu95, and Leu96. Interestingly,
inhibitor 12 showed an interaction with Asn222 in the marmoset
enzyme (23.3 kcal mol
21), which was not observed for Ser222 in
Table 2. Free energy calculations for the MD simulations of the four docking complexes.
comp ELEC VDW GAS PBSOL PBTOT (DGbind) TSTOT DG
mean mean mean mean (±SE) mean (±SE) mean (±SE)
Human x-ray structure (1fdtB)
12 215.4 240.4 255.7 35.1 220.663.8 215.966.6 24.767.6
19 236.7 250.1 286.8 64.2 222.665.0 215.366.8 27.368.4
Marmoset monkey homology model
12 224.5 238.1 261.3 40.0 221.364.9 215.465.3 25.867.2
19 242.2 234.4 276.5 50.3 226.364.4 223.164.3 23.266.1
DG and DGbind values correspond to the longest stable plateau for each MD. (DG) free binding energy; (PBTOT)( DGbind) relative binding energy; (ELEC) electrostatic
contribution in gas phase; (VDW) Van der Waals contribution in gas phase; (GAS) free energy in vacuum; (PBSOL) solvation energy; (TSTOT)( TDS) entropic
contribution; (mean) mean value; (SE) standard error of the mean; all energies expressed in kcal mol
21.
doi:10.1371/journal.pone.0022990.t002
Table 3. Interaction energies between the inhibitors 12 and 19 and the proximal (4.0 A ˚) binding site residues of human 17b-HSD1.
comp Gly94 Leu95 Leu96 Ser142 Leu149 Asn152 Tyr155 Cys185 Gly186 Pro187
12 21.8 20.3 21.2 21.3 22.2 24.1 21.5 20.2 20.4 21.3
19 20.7 20.7 21.7 21.3 22.0 25.7 22.6 20.3 20.8 22.0
comp Phe192 Met193 Tyr218 His221 Ser222 Val225 Arg258 Phe259 Leu262 Glu282
12 21.2 21.0 20.7 21.8 20.8 21.7 20.1 21.2 20.4 20.1
19 21.8 21.9 20.1 20.2 20.4 21.9 20.5 20.9 20.3 24.3
All energies are expressed in kcal mol
21.
doi:10.1371/journal.pone.0022990.t003
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21). This is not the case for 19,
as the interaction with Asn222 (20.3 kcal mol
21) does not
contribute significantly to the interaction energy. In addition to
Leu149, Pro187, Met193, Ile225, and Phe259, which interact with
both compounds in the human enzyme, Gly186, His221, and
Asn282 significantly contribute to the binding of 12 and 19 to
marmoset 17b-HSD1 with interaction energies in the range from
20.4 kcal mol
21 to 23.6 kcal mol
21. Interestingly, in marmoset
17b-HSD1 the interaction energy between 12 and Asn282
(23.2 kcal mol
21) is 32 fold increased compared to that with
Glu282 in the human enzyme (20.1 kcal mol
21). In marmoset
17b-HSD1 an increased energy is also observed for the interaction
of compound 19 with His221 (22.6 kcal mol
21) compared to the
human enzyme (20.2 kcal mol
21).
Discussion
When the three-dimensional structures of marmoset and human
17b-HSD1 are compared, one of the most striking features is the
small a-helix including the residues 190 to 196. It is formed in the
segment between the bF-sheet and the aG’-helix starting from the
interface residue Thr190, which is half in and half out of the helix
(N-cap position). In contrast to the human enzyme, where this
region is highly flexible, as suggested by the different crystal
structures, the a-helix stayed stable during the MD simulation in
both the holoform and the ternary complex. The observed
conformational stability might be explained by the presence of a
proline in position 191 instead of an alanine. Proline is a
favourable candidate for N1 position because of its own
conformational properties: with only one rotatable angle it loses
less entropy than other amino acids in forming an a-helix and
thereby it should have some stabilizing influence [47]. Further-
more, in an analysis of sequence-structural characteristics in
protein crystal structures, proline was found to be a favoured
residue at N1 position. Especially the residue pair involving
threonine at N-cap and proline at N1 position, which is observed
for marmoset 17b-HSD1, has a high prevalence [48].
In order to analyse the influence of the conformational changes
in marmoset 17b-HSD1 on ligand binding, docking studies with
subsequent MD simulations, free energy calculations, and energy
decomposition analyses were carried out. While the conforma-
tional differences between the marmoset and the human enzyme
did not affect the binding mode of 12 remarkably, the suggested
binding mode of 19 differed strongly in 17b-HSD1 of both species.
One possible explanation for that might be the lower sterical
demand of 12 compared to 19. However, the energy contribution
of the interaction between 12 and the marmoset Asn152 is
reduced, whereas it was outstanding in complex with the human
enzyme. Due to the minimal shift of 12 in the marmoset binding
pocket, the geometric parameters for the H-bond with Asn152 are
no longer optimal. Interestingly, in the marmoset enzyme an
additional interaction of 12 with Asn222 is observed, which seems
to compensate the deficit in interaction energy due to the absent
interaction with Asn152 resulting in comparable binding energies
for 12 in complex with human and marmoset 17b-HSD1. The
latter finding is in accordance with the inhibition data observed for
compound 12 and validates the marmoset 17b-HSD1 model.
Considering compound 19, no particular interactions with the
subpocket residues of the marmoset enzyme exist. Although weak
interactions between 19 and the C-terminal region of marmoset
17b-HSD1 are observed, the binding free energy is less favourable
compared to that calculated for the human 17b-HSD1-19
complex. As the C-terminal part of the enzyme has already been
discussed as a potential product exit gate of the enzyme [21],
inhibitor 19 might be solvent exposed. This is consistent with the
unfavourable entropy term of this complex resulting in the least
favourable free energy.
Obviously, the presence of a proline in the flexible loop region
and the thereby induced conformational changes in marmoset
17b-HSD1 are decisive for the species specific inhibition of 19.O n
one hand interactions with subpocket residues like Asn152,
recently discussed as relevant interaction partner [49], are
prevented and on the other hand the inhibitor is forced in an
unfavourable solvent exposed conformation.
The bis(hydroxyphenyl) substituted arenes (compounds 1–11)
show similar or increased inhibitory potencies toward marmoset
17b-HSD1 when comparing to human 17b-HSD1. Recently
performed docking experiments proposed a steroidal binding
mode when the human crystal structure 1fdtB was used [33]. The
high inhibitory potencies toward marmoset 17b-HSD1 are in
concert with the modelled structure of marmoset 17b-HSD1 as
steroid-like binding is not affected by the proposed conformational
changes. Obviously, they even stabilize the bis(hydroxyphenyl)
substituted arenes in the marmoset 17b-HSD1 binding pocket as
indicated by the observed inhibitory potencies.
Differing inhibitory potencies toward human 17b-HSD1 and
17b-HSD2 may arise from sequence variations in the regions 94–
196 and 214–284 (numbering according to 17b-HSD1), which
might lead to differences in the active sites of the two human
subtypes. A lower selectivity of compounds toward non-target
marmoset 17b-HSD2 was observed, when comparing to human
17b-HSD2. Obviously, the differences in the active sites of
marmoset 17b-HSD1 and 17b-HSD2 are less pronounced
compared to the human orthologs. However, as the available
marmoset 17b-HSD2 sequence is missing the F/G segment and
the C-terminal part this hypothesis cannot be proved.
Table 4. Interaction energies between the inhibitors 12 and 19 and the proximal (4.0 A ˚) binding site residues of marmoset
monkey 17b-HSD1.
comp Gly94 Leu95 Leu96 Ser142 Leu149 Asn152 Tyr155 Cys185 Gly186 Pro187
12 20.0 20.1 20.8 22.1 22.0 21.6 20.8 20.3 20.7 22.0
19 20.0 20.1 20.2 20.9 21.1 20.2 20.3 23.5 22.0 22.0
comp Phe192 Met193 Tyr218 His221 Asn222 Ile225 Arg258 Phe259 Leu262 Asn282
12 20.4 21.3 21.4 20.8 23.3 21.9 20.1 21.3 20.9 23.2
19 20.0 20.4 20.0 22.6 20.3 22.6 23.7 21.9 21.0 23.6
All energies are expressed in kcal mol
21.
doi:10.1371/journal.pone.0022990.t004
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substantiated by its ability to explain the reduced inhibitory
potency of C-15 substituted estrone derivatives toward marmoset
17b-HSD1 [39]. The substituents in 15-position of the steroid
were designed to occupy the hole between the flexible bFaG’-loop
and the aG’-helix in the human enzyme [50]. Together with the
helix formation and the conformational changes in the bD/aE-
segment, the S222N mutation limits the size of the hole in
marmoset 17b-HSD1 and thereby might reduce the inhibitory
potency toward the marmoset enzyme.
Conclusion
An elegant strategy to gain more knowledge of active site
topologies and, in particular, of protein-ligand interactions is to
compare inhibition values obtained for one compound toward
ortholog proteins from various species, which are highly conserved
in sequence and differ only in few residues. Thereby, such an
approach can be a valid alternative to site-directed mutagenesis.
As human and marmoset 17b-HSD1 enzymes meet these criteria,
selected human 17b-HSD1 inhibitors were assessed for their
inhibitory potencies toward marmoset 17b-HSD1. While a species
specific inhibition profile was observed in the class of the
(hydroxyphenyl)naphthols, representatives of the other evaluated
compound classes showed similar or even higher inhibition
compared to those observed for the human enzyme. Using a
combination of computational methods, including homology
modeling, molecular docking, MD simulation, and binding energy
calculation, a reasonable model of the three-dimensional structure
of marmoset 17b-HSD1 was developed and inhibition data were
rationalized on the structural basis. In the marmoset 17b-HSD1,
residues 190 to 196 form a small a-helix, which is obviously
stabilized by the presence of a proline in N-cap position (residue
191) and induces conformational changes that affect ligand
binding. Furthermore energy decomposition analysis highlighted
the important role of Asn152 as interaction partner for inhibitor
binding.
This work could not only offer a better understanding of the
active site topologies and of the protein-ligand interactions, but
also provides novel structural clues that will help to design and
optimize potent human 17b-HSD1 inhibitors with improved
inhibitory potency toward marmoset 17b-HSD1. This is an
important step to turn compounds, which show a promising
pharmaceutical profile, into candidates for in vivo evaluation. Thus,
our combined computational approach could also be considered
as a valuable tool to achieve this goal.
Methods
Sequence Alignment and Model Building
The amino acid sequences of rat (accession number P51657),
mouse (P51656) cynomolgus (Q4JK77) and marmoset 17b-HSD1
(Q9GME2) as well as human (P37059), cynomolgus (Q4JK76),
marmoset (Q9GME5), mouse (P51658) and rat (Q62730) 17b-
HSD2 were obtained from the uniprot webpage. These sequences
were pairwise aligned with human 17b-HSD1 (PDB code: 1fdt)
using MAFFT version 5 [51]. Using this alignment, a set of 100
comparative models of marmoset 17b-HSD1 was built employing
Modeller9v7 [42], with the ternary complex E1-NADPH-human
17b-HSD1 as template. This complex resulted from docking of E1
to human 17b-HSD1 (PDB code: 1fdtB) (see below). The best
homology model was then selected according to the Modeller
energy score, DOPE score [43] and PROCHECK [44] tests. The
reliability of the built homology models was checked by Prosa2003
[52] (Fig. S1), ERRAT [53], and Verify3D [54] (Fig. S2).
MD Simulations
MD simulations were performed using the AMBER 9.0 suite
program [55]. The partial atomic charges for E1 and the inhibitors
were derived from the molecular electrostatic potential (MEP)
previously calculated using GAMESS [56], according to the RESP
methodology[57]. For the protein,partialatomiccharges wereread
from the AMBER 9.0 libraries. The AMBER99SB force field [58]
was employed to define atom types and potentials for the protein,
while the general AMBER force field (gaff) [59] was used to define
all needed atom types and parameters for E1 and the inhibitors. For
NADPH (charge 24), the parameters previously reported by Ulf
Ryde were applied (http://www.teokem.lu.se/,ulf/).
The input files for the MD simulation were prepared with the xLEaP
module of AMBER. Each system was solvated with an octahedral box of
TIP3P water molecules of 10 A ˚ radius and neutralized by the addition of
Na
+ions. Finally, for each complex the topology and the coordinate files
were written and used in the MD simulations.
Before starting the production-run phase, the following equilibra-
tion protocol was applied to all systems. At the beginning the system
was energy-minimized in two stages: firstly, the solvent was relaxed
while all the solute atoms were harmonically restrained to their
original positions with a force constant of 100 kcal mol
21 A ˚ 22 for
1000 steps; and secondly, the whole molecular system was minimized
for 2500 steps by conjugate gradient. Subsequently, the system was
heated during 60 ps from 0 to 300 K at constant volume conditions
(NTV, PBC conditions), and then equilibrated keeping both
temperature and pressure constant (NTP, PBC conditions, 300 K,
1 atm) during 100 ps. Electrostatic interactions were computed using
the Particle Mesh Ewald method [60], and the SHAKE [61]
algorithm was employed to keep all bonds involving hydrogen atoms
rigid. NADPH, E1 and the inhibitors were constrained during the
equilibration with a force constant of 20 kcal mol
21 A ˚ 22.A f t e r
equilibration, a MD production stage (NTP, PBC conditions, 300 K,
1 atm) was performed. The total simulation length differed for the
various complexes ranging from 4 to 6 ns. Distance restraints were
applied to substrate/inhibitor with the aim of maintaining their
proper orientation at the beginning (first ns) of production stage.
For the ternary complex of marmoset 17b-HSD1 with E1 and
NADPH, two additional distance restraints were used: between
the keto-oxygen of E1 and the side chain oxygen of Ser142
(d=2.40–3.00 A ˚; force constant: 10 kcal mol
21 A ˚ 22) and be-
tween the oxygen of the OH-group in 17-position of E1 and the
NE2 nitrogen of the His221 side chain (d=2.70–3.40 A ˚; force
constant: 10 kcal mol
21 A ˚ 22).
For the ternary complex of human 17b-HSD1 with 12 and
NADPH, three additional distance restraints were used: between
the keto-oxygen of 12 and the side chain oxygen of Tyr155
(d=2.80–3.40 A ˚; force constant: 10 kcal mol
21 A ˚ 22), between
the oxygen of the OH-group in meta-position of 12 and the OD1
oxygen of the Asn152 side chain (d=2.70–3.30 A ˚; force constant:
10 kcal mol
21 A ˚ 22), and between the oxygen of the para OH-
group of 12 and the NE2 nitrogen of the His221 side chain
(d=2.70–3.30 A ˚; force constant: 10 kcal mol
21 A ˚ 22).
For the ternary complex of marmoset 17b-HSD1 with 12 and
NADPH three additional distance restraints were used: between
the keto-oxygen of 12 and the side chain oxygen of Ser142
(d=2.50–3.10 A ˚; force constant: 10 kcal mol
21 A ˚ 22), between
the oxygen of the OH-group in meta-position of 1 and the OD1
oxygen of the Asn152 side chain (d=2.40–3.00 A ˚; force constant:
10 kcal mol
21 A ˚ 22), and between the oxygen of the para OH-
group of 12 and the OD1 oxygen of the Asn282 side chain
(d=2.50–3.10 A ˚; force constant: 10 kcal mol
21 A ˚ 22).
For the ternary complex of human 17b-HSD1 with 19 and
NADPH three additional distance restraints were used: between
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and the side chain oxygen of Tyr155 (d=2.80–3.40 A ˚; force
constant: 10 kcal mol
21 A ˚ 22), between the oxygen of the OH-
group in meta-position of the phenyl ring and the NE2 nitrogen
of the His221 side chain (d=3.00–4.20 A ˚; force constant:
10 kcal mol
21 A ˚ 22), and between the nitrogen of the sulfonamide
moiety of 19 and the OD1 oxygen of the Asn152 side chain
(d=2.70–3.40 A ˚; force constant: 10 kcal mol
21 A ˚ 22).
For the ternary complex of marmoset 17b-HSD1 with 19 and
NADPH two additional distance restraints were used: between the
oxygen of the OH-group in 2-position of the naphthol core and
the NE2 nitrogen of the His221 side chain (d=2.70–3.40 A ˚; force
constant: 10 kcal mol
21 A ˚ 22) and between the oxygen of the OH-
group in meta-position of the phenyl ring of 19 and the backbone
carbonyl oxygen of Cys185 (d=2.40–3.00 A ˚; force constant:
10 kcal mol
21 A ˚ 22).
Trajectories were analyzed using the AMBER ptraj module, the
MMTSB toolset [62] and the molecular visualization program VMD
(Visual Molecular Dynamics) [63]. The resulting low energy structures
were extracted forthe homology model (apoform and ternary complex)
and subjected to a subsequent minimization of 1000 steps (500 steps of
steepest descent followed by 500 steps of conjugate gradient), using the
sander module of AMBER. The modified generalized Born solvation
model (IGB=2) [64] was used. Active site volumes of low energy
structures were calculated using the CASTp [45].
Molecular docking
The three-dimensional structures used for docking studies were
either retrieved from the PDB (1fdt, conformation B for residues
187–200) or from the homology modelling with subsequent MD
simulation (equilibrated ternary complex after 5537 ps). The
cocrystallized E2 and water molecules were removed from the
PDB file. Hydrogen atoms and neutral end groups were added,
NADP
+ was turned into NADPH and correct atom types were set.
Ionization states and hydrogen positions were assigned using the
Protonate 3D utility of MOE2009.10 (Chemical Computing
Group Inc., Montreal, Canada). Ligand structures were built in
MOE and RESP charges were assigned as described above. The
17b-HSD1 three-dimensional structures and ligand structures
were prepared for docking studies through the graphical user
interface AutoDockTools4 [46]. For the ligands, non-polar
hydrogen atoms were deleted, rotatable bonds were defined and
RESP charges were kept. For the protein, non-polar hydrogen
atoms were deleted and charges were added to the structure.
Autodock4.2 [46] was used to dock the ligands in the steroidal
binding site of the processed protein structures. A box, centered on
the steroid-binding site, was set to define the docking area. Grid
points of 90690690 with 0.250 A ˚ spacing were calculated around
the docking area for all the ligand atom types using AutoGrid4.2.
For each inhibitor, 50 separate docking calculations were
performed. Each docking calculation consisted of 25610
5 energy
evaluations using the Lamarckian genetic algorithm local search
(GALS) method. Each docking run was performed with a
population size of 250. A mutation rate of 0.02 and a crossover
rate of 0.8 were used to generate new docking trials for subsequent
generations. The docking results from each of the 50 calculations
were clustered on the basis of root-mean-square deviation
(RMSD=2.0 A ˚) between the Cartesian coordinates of the ligand
atoms and were ranked on the basis of the free binding energy.
Free energy calculations using the MM/PBSA method
The calculation of binding free energy was evaluated using the
MM/PBSA (Molecular Mechanics/Poisson Boltzmann Surface
Area) method as implemented in AMBER11 [65]. The electronic
and Van der Waals energies were calculated using the sander
module in AMBER11. The solvation free energy contributions
may be further decomposed into an electrostatic and hydrophobic
contribution. The electrostatic portion is calculated using the
linearized PB equation. The hydrophobic contribution is approx-
imated by the LCPO method [66] implemented within sander.
The changes in entropy upon ligand association DS are estimated
by normal mode analysis. For stable plateaus of the MD
trajectories, snapshots were collected every 20
th frame (every
20 ps) and used to calculate relative binding affinity (DGbind) and
absolute free energy (DG).
Energy decomposition using the MM/GBSA method
A free energy decomposition of the protein ligand complexes
was performed on a pairwise per-residue basis using the MM/
GBSA (Molecular Mechanics/Generalized Born Surface Area)
method as implemented in AMBER11. The GBSA implicit-
solvent solvation model was used in order to avoid the retarding
effect of the PBSA method.
Inhibition assay
[2, 4, 6, 7-
3H]-E1 and [2, 4, 6, 7-
3H]-E2 were bought from
Perkin Elmer, Boston. Quickszint Flow 302 scintillator fluid was
bought from Zinsser Analytic, Frankfurt. Marmoset 17b-HSD1
and 17b-HSD2 were obtained from marmoset placenta according
to previously described procedures [41]. Fresh marmoset placenta
was homogenized and cytosolic and microsomal fractions were
separated by centrifugation. For the partial purification of 17b-
HSD1, the cytosolic fraction was precipitated with ammonium
sulfate. 17b-HSD2 was obtained from the microsomal fraction.
Inhibition of 17b-HSD1. Inhibitory activities were evaluated
by an established method with minor modifications [41]. Briefly,
the enzyme preparation was incubated with NADH [500 mM] in
the presence of potential inhibitors at 37uC in a phosphate buffer
(50 mM) supplemented with 20% of glycerol and EDTA (1 mM).
Inhibitor stock solutions were prepared in DMSO. The final
concentration of DMSO was adjusted to 1% in all samples. The
enzymatic reaction was started by addition of a mixture of
unlabelled- and [2, 4, 6, 7-
3H]-E1 (final concentration: 500 nM,
0.15 mCi). After 10 min, the reaction was stopped by the addition
of HgCl2 (10 mM) and the mixture was extracted with
diethylether. After evaporation, the steroids were dissolved in
acetonitrile. E1 and E2 were separated using acetonitrile/water
(45:55) as mobile phase in a C18 reverse phase chromatography
column (Nucleodur C18 Gravity, 3 mm, Macherey-Nagel, Du ¨ren)
connected to an HPLC-system (Agilent 1200 Series, Agilent
Technologies, Waldbronn). Detection and quantification of the
steroids were performed using a radioflow detector (Agilent 1200
Series, Agilent Technologies, Waldbronn). The conversion rate
was calculated after analysis of the resulting chromatograms
according to the following equation: %conversion~
%E2
%E2z%E1
|100. Each value was calculated from at least three independent
experiments.
Inhibition of 17b-HSD2. The 17b-HSD2 inhibition assay
was performed similarly to the 17b-HSD1 procedure. The
microsomal fraction was incubated with NAD
+ [1500 mM], test
compound and a mixture of unlabelled- and [2,4, 6, 7-
3H]-E2 (final
concentration: 500 nM, 0.11 mCi) for 20 min at 37uC. Further
treatment of the samples and HPLC separation was carried out as
mentioned above. The conversion rate was calculated after analysis
of the resultingchromatograms accordingto the followingequation:
%conversion~
%E1
%E1z%E2
|100.
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Figure S1 Energy profile drawn for the marmoset 17b-
HSD1 model using PROSA. Energy profiles of marmoset 17b-
HSD1 in complex with NADPH (orange) and of marmoset 17b-
HSD1 in complex with NADPH and E1 (green).
(TIF)
Figure S2 Verify3D results for the marmoset 17b-HSD1
model. Verify-3D results are shown for the secondary complex of
marmoset 17b-HSD1 (orange) with NADPH and for ternary
complex (green) with NADPH and E1; residues with positive score
are reasonably folded.
(TIF)
Table S1 Cluster analysis of molecular docking results.
All energies are expressed in kcal mol
21. The lowest energy
conformation of each cluster, which is marked in bold was used for
further investigation.
(DOC)
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